<DOC>
	<DOCNO>NCT01567813</DOCNO>
	<brief_summary>This post-licensure safety observation cohort study describe general safety GARDASIL™ ( quadrivalent human papillomavirus vaccine ) male .</brief_summary>
	<brief_title>Post-Licensure Study Safety GARDASIL™ Males ( V501-070 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<criteria>Inclusion criterion : Male vaccinate least one dose GARDASIL™ October 2009 FDA date first licensure GARDASIL™ male Exclusion criterion cohort : Female Male vaccinate prior October 2009 FDA date first licensure GARDASIL™ male Male receive dos GARDASIL™ outside health plan Exclusion criterion , Regimen Completers cohort : Male &lt; 9 &gt; 26 year age first dose Male part health plan dose 3dose vaccination regimen give period &gt; 12 month Less 28day interval first second dose Less 12 week second third dose Less 24 week first third dose Exclusion criterion , Autoimmune cohort : Male le 12 month health plan membership prior first dose GARDASIL™</criteria>
	<gender>Male</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Warts</keyword>
	<keyword>Papillomavirus infection</keyword>
	<keyword>DNA virus infection</keyword>
	<keyword>Virus disease</keyword>
	<keyword>Skin disease , viral</keyword>
	<keyword>Tumor virus infection</keyword>
	<keyword>Skin disease , infectious</keyword>
	<keyword>Skin disease</keyword>
</DOC>